Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network
暂无分享,去创建一个
A. Stamatoullas | K. Götze | E. Solary | S. Chevret | M. Lübbert | E. Wattel | P. Fenaux | A. Patriarca | S. Thépot | L. Adès | N. Droin | U. Germing | R. Itzykson | A. Giagounidis | R. Sapena | U. Platzbecker | V. Santini | G. Metzgeroth | G. Zini | J. Goasguen | M. Morabito | F. Onida | N. Jaekel | S. Nimubona | S. Mossuto | C. Chaffaut | S. Gloaguen | R. Navarro | Martin Puttrich | Fatiha Chermat | Sophie Park | J. Torregrosa Diaz | A. Pelizzari
[1] M. Voso,et al. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. , 2019, Blood reviews.
[2] H. Kantarjian,et al. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. , 2018, Blood advances.
[3] O. Abdel-Wahab,et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia , 2017, Leukemia.
[4] Xue-chun Lu,et al. A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis , 2017, Annals of Hematology.
[5] E. Solary,et al. How I treat chronic myelomonocytic leukemia. , 2017, Blood.
[6] M. Konopleva,et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents , 2017, American journal of hematology.
[7] Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents , 2017, Blood cancer journal.
[8] M. Cazzola,et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. , 2016, Blood.
[9] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[10] M. Cazzola,et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. , 2015, Blood.
[11] P. Cauchy,et al. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia , 2014, Leukemia.
[12] R. Laborde,et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes , 2013, Leukemia.
[13] J. Maciejewski,et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. , 2013, Leukemia research.
[14] L. Arenillas,et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. , 2013, Blood.
[15] A. Vekhoff,et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. , 2011, Blood.
[16] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[17] H. Byun,et al. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition , 2007, British journal of haematology.